Trial Profile
An Extension Study of ABT-806 for Subjects With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2017
Price :
$35
*
At a glance
- Drugs Depatuxizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 26 Jan 2017 Status changed from active, no longer recruiting to completed.
- 25 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 25 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.